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Hypoxic-ischaemic encephalopathy (HIE) remains a leading cause of neonatal death and adverse 
neurodevelopmental outcome, affecting 2-4 in 1000 live births. In cases of moderate to severe HIE, 
the current standard of care in near-term or term infants is therapeutic hypothermia initiated within 6 
hours of the asphyxic insult. Preclinical and clinical studies have been fundamental in establishing the 
optimal temperature reduction (3°-5°C) and treatment duration (up to 72h); and importantly have 
shown that longer or deeper cooling protocols do not improve neuroprotection and in some instances 
have even demonstrated decreased efficacy. Furthermore, as 8-9 infants need to be treated with 
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(Edwards et al., 2010), there remains a clear need to identify adjunct therapies that can further 
improve outcomes for this vulnerable population. 
 
One such adjunct therapy is erythropoietin (Epo), which has been demonstrated in preclinical studies 
and a small number of clinical studies to reduce cellular signs of brain injury, macroscopic evidence of 
injury as assessed by MRI, and result in trends towards improved clinical outcomes in HIE. Moreover, 
it is an attractive neuroprotective agent as it has an essential role for normal neurodevelopment and 
has been implicated in injury repair mechanisms through eliciting acute (anti-apoptotic, anti-
inflammatory, anti-oxidant and anti-excitotoxic) and regenerative (angiogenesis, neurogenesis, 
oligodendrogenesis) mechanisms. In addition, the pharmacokinetics of high dose recombinant (rEpo) 
are now well defined and importantly, it has also been shown to be safe when given in combination 
with hypothermia in neonates with HIE (Wu et al., 2012). 
 
In this issue of The Journal of Physiology, Wassink et al., (2020) investigate whether high-dose rEpo 
combined with moderate hypothermia in a fetal sheep model of severe global cerebral ischaemia 
provides added neuroprotection over hypothermia alone. To ensure clinical relevance, their protocol 
included delayed onset of both hypothermia and treatment, with the infusion of high-dose rEpo 
initiated 3 hours after the ischaemic insult. Importantly, whilst independently neuroprotective in 
comparison to the ischaemia-vehicle, Wassink et al., (2020) found there was no enhanced benefit 
from combining rEpo with therapeutic hypothermia on assessment of both physiological parameters 
(EEG, heart rate, carotid artery blood flow) and cellular histology. Of added concern, ischaemia-rEpo-
hypothermia was also associated with increased cortical caspase-3 positive cells, suggesting increased 
ongoing cell death even after 7 days of recovery in the combined therapy group.  
 
Although the results of Phase 3 clinical trials of rEpo are still awaited, this study highlights existing 
concerns about its efficacy as an adjunct clinical therapy for HIE. Along with rEpo, several other agents 
have also been identified through preclinical studies as promising post-natal adjunct therapies to 
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unfortunately none have been able to demonstrate significant effects as adjunct agents with 
therapeutic hypothermia in a large clinical trial. Xenon, a monoatomic gas which readily crosses the 
blood-brain barrier, was found to be of significant benefit in preclinical studies but when taken to a 
randomised control trial, there was no added benefit when inhaled Xenon was combined with 
therapeutic hypothermia (Azzopardi et al., 2016). Melatonin similarly is known to cross the blood 
brain barrier and is an endogenous hormone which is thought have a key role in neural repair through 
reducing oxidative stress. Although a single small clinical study (Aly et al., 2015) described significant 
improvements in MRI white matter appearances and short term developmental outcome, a larger 
scale clinical trial has not been completed. Moreover, the promising results of pre-clinical piglet 
studies should be considered with caution as effectiveness with delayed initiation of treatment and 
the potentially adverse effects of the ethanol used as a diluent to deliver melatonin have not been 
studied in detail (Robertson et al., 2013; Davidson et al., 2015). There are also several clinical trials in 
progress of autologous stem cells derived from cord blood or the placenta, although their precise 
mechanism of action for this application is still unclear and thus defining their optimal use remains 
challenging (Bennet et al., 2012). 
 
So for now, as the search continues, where to next? It is important to consider that the success of 
therapeutic hypothermia was achieved through a bench to bedside translational pathway which 
included first establishing the cellular nature and delayed natural history of the underlying brain 
injury, the mechanisms of potential neuroprotection and then the optimal delivery of the therapy. A 
vital step in this pathway is therefore to also have preclinical models and protocols which can 
recapitulate the conditions and standards of clinical care to maintain relevance. Through this, it is 
likely that the key to identifying the next adjunct therapy will be to understand how the mechanism of 
action of any potential agent interacts with and hopefully directly complements hypothermia; rather 
than acting through the same biological route and potentially competing/interfering with 
hypothermic neuroprotection as appears to be the case with rEpo. Any novel therapy must also be 
feasible to deliver in the clinical environment, have a favourable risk/benefit ratio, all within the 
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